Published in Mod Pathol on February 20, 2015
-Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol (2015) 4.31
Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials. J Clin Oncol (2016) 1.52
Digital image analysis outperforms manual biomarker assessment in breast cancer. Mod Pathol (2016) 0.86
Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. Mod Pathol (2016) 0.85
Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up. Breast Cancer Res Treat (2016) 0.82
[Histological grading of breast cancer]. Pathologe (2016) 0.81
Reproducibility of the NEPTUNE descriptor-based scoring system on whole-slide images and histologic and ultrastructural digital images. Mod Pathol (2016) 0.81
Ki67-An unsuitable marker of gastric cancer prognosis unmasks intratumoral heterogeneity. J Surg Oncol (2015) 0.78
Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer. J Clin Oncol (2016) 0.77
Prognostic significance of Ki67 in Chinese women diagnosed with ER(+)/HER2(-) breast cancers by the 2015 St. Gallen consensus classification. BMC Cancer (2017) 0.75
Associations of Prostate-Specific Antigen, Prostate Carcinoma Tissue Gleason Score, and Androgen Receptor Expression with Bone Metastasis in Patients with Prostate Carcinoma. Med Sci Monit (2017) 0.75
Synaptophysin-Ki67 double stain: a novel technique that improves interobserver agreement in the grading of well-differentiated gastrointestinal neuroendocrine tumors. Mod Pathol (2017) 0.75
Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer. Oncotarget (2017) 0.75
High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer. Oncologist (2016) 0.75
A comparison of Ki-67 counting methods in luminal Breast Cancer: The Average Method vs. the Hot Spot Method. PLoS One (2017) 0.75
Value of Breast Cancer Molecular Subtypes and Ki67 Expression for the Prediction of Efficacy and Prognosis of Neoadjuvant Chemotherapy in a Chinese Population. Medicine (Baltimore) (2016) 0.75
Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage 'pure' and 'mixed' lobular breast cancer. J Exp Clin Cancer Res (2016) 0.75
Quality assurance trials for Ki67 assessment in pathology. Virchows Arch (2017) 0.75
Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors. Mod Pathol (2017) 0.75
Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial. Lancet Oncol (2014) 1.55
Circulating tumor cells. Prog Mol Biol Transl Sci (2010) 1.12
Origin and characteristics of adverse events in aromatase inhibition therapy for breast cancer. Semin Oncol (2003) 0.82
The genomic landscape of breast cancer and its interaction with host immunity. Breast (2016) 0.79
Risk of recurrence estimates with IHC4+C are tolerant of variations in staining and scoring: an analytical validity study. J Clin Pathol (2015) 0.78
Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma. JAMA Oncol (2016) 0.78
Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration. NPJ Breast Cancer (2016) 0.76